Roger Newton has worked for 29 years in the pharmaceutical and life sciences industries. He is currently Founder, President & CEO, and a Director of Esperion Therapeutics, which has its laboratories and offices at the Michigan Life Science and Innovation Center in Plymouth, MI. Prior to his current role, he was Senior Vice President, Pfizer Global R&D, and Director, Esperion Therapeutics, a Pfizer. company. He was a Co-founder, President & CEO of the original Esperion founded in July 1998. Under Roger's leadership and the team's effort, Esperion raised more than $200 million in funding, building a portfolio of biopharmaceuticals focusing on HDL therapy and small molecule lipid regulating agents. Esperion was acquired by Pfizer for $1.3 billion in February 2004 and was run as a separate unit within Pfizer until its closure in May 2007. Roger divested Esperion IP and the company name from Pfizer in May 2008 and restarted the company as an independent enterprise with $23 million in venture capital. Prior to founding the original Esperion, Roger was with Warner Lambert/Parke-Davis from 1981-1998. As a Distinguished Research Fellow and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor).
Roger's research interests for the past 38 years have focused on the nutritional and pharmacological regulation of cholesterol and lipoprotein metabolism as they relate to atherosclerosis and vascular diseases. Roger is an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored nearly one hundred peer-reviewed articles and chapters during his research career. Roger has a Ph.D. in nutrition from the University of California, Davis, a Master of Science degree in nutritional biochemistry from the University of Connecticut, and a Bachelor of Science degree in biology from Lafayette College.
Roger is a member of the Board of Directors of Juventas Therapeutics, Rubicon Genomics, and Ann Arbor Spark. He is a member of the National Advisory Boards of the University of Michigan Cardiovascular Center and University of Michigan Life Sciences Institute. He is also a member of the Technology Advisory Boards of Arboretum Ventures and Metagenics, Inc
August 27, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.